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Abstract
Objective: To review the treatment choices of women with complete androgen 
insensitivity syndrome (CAIS) at a single tertiary centre.
Design: Retrospective review.
Patients: Women with CAIS identified from our database.
Results: The study group comprised 141 women with CAIS. Eleven percent (16/141) of 
women had gonads in situ, 3 of whom were under workup for gonadectomy. The age 
of gonadectomy in the remainder 125 women was 17 (0.1–53) years. The most common 
form of HRT was oral oestrogen or transdermal oestrogen in 80% (113/141). 13/141 
(9%) women used vaginal oestrogens alone or together with other forms of HRT. 
Testosterone preparations had been used by 17% (24/141) of women and were currently 
used in 10% (14/141). Of those who had used testosterone, 42% (10/24) had chosen not 
to continue after a therapeutic trial.
Conclusions: In a clinic offering individualised multidisciplinary care for women with 
CAIS, we found that the majority of women chose oestrogen-based treatment while a 
significant minority used testosterone.
Introduction
Complete androgen insensitivity syndrome (CAIS) is one 
of the most common disorders of sex development (DSD) 
caused by mutations of the androgen receptor gene. 
The estimated prevalence of AIS is 4.1 per 100,000 live 
born females (1). Testes develop in the presence of the Y 
chromosome, but the lack of androgen receptor activity 
results in a typical female phenotype. The anti-Mullerian 
hormone produced by the gonads causes regression of 
the uterus, cervix and proximal vagina during foetal 
development. Common clinical presentations include 
inguinal or labial hernia in childhood or primary 
amenorrhoea in adolescence (1). CAIS may also present 
through screening after a family member is affected 
or discordance between prenatal sex prediction and 
phenotype at birth (1).
Traditionally, prophylactic gonadectomy has been 
advised because of the risk of malignancy of the intra-
abdominal testes, which ranges from 0 to 30% (2). 
Current practice is to recommend gonadectomy after 
completion of puberty (2). Hormone replacement therapy 
(HRT) is required after gonadectomy in order to maintain 
secondary sexual characteristics, bone and cardiovascular 
health and to promote general wellbeing and sexual 
function. In the study by Berglund and coworkers, 64/78 
women with AIS were on HRT and the median age at 
first prescription of HRT was 14 years (1). Sex steroid 
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replacement has traditionally been based on types of 
oestrogen, but there is increasing interest from user groups 
in the use of testosterone, which in this situation is used 
as a prohormone providing oestradiol via aromatisation. 
As women with CAIS do not have a uterus, progesterone 
is not required.
Based on our clinical experience, interest in the use of 
testosterone in women with CAIS has developed through 
observations voiced from user groups, particularly women 
who experienced late gonadectomy. Unlike younger age 
groups, those who have gained a sense of a ‘testosterone 
milieu’ after gonadarche are in a good position to make a 
comparison with a post-gonadectomy ‘oestrogen milieu’. 
The reported differences between these two situations 
include altered vitality, libido and athletic performance. 
Of course, the psychosocial effects of a difficult diagnosis, 
which often coincides with gonadectomy, may contribute 
to such symptoms, and it is accepted that wellbeing is not 
solely hormone related.
As there are no known adverse effects of long-term 
exposure to testosterone in women with CAIS who have 
declined gonadectomy and in the absence of guidelines 
on the most appropriate HRT for this group of women, 
our clinic philosophy has been to offer choice and follow 
individual preference. Here, we reviewed our experience 
on HRT choices made by women with CAIS.
Subjects and methods
The study was a retrospective analysis of women with CAIS 
seen at the University College London Hospital (UCLH), 
a tertiary referral centre for DSD. Management is by a 
multidisciplinary team comprising an endocrinologist, 
gynaecologist, nurse specialist and clinical psychologist. 
The clinical diagnosis of CAIS was based on an 
unambiguous female phenotype, scant body hair, 46,XY 
karyotype, testicular histology and absent uterus (3). 
Androgen receptor mutation testing was not performed 
routinely when the clinical diagnosis was clearcut and 
only performed if the carrier status of sisters was in 
question. Women were followed up every 2–6 months at 
the start of hormonal therapy, and the follow-up spaced 
out to annual visits when stable. Side effects were asked at 
the clinic visits and information of their HRT was input 
into our database.
Oestrogen replacement options in the United 
Kingdom favour the use of oestradiol valerate or alternative 
esters. Conjugated equine oestrogens are gradually being 
phased out because of the increased risk of thrombosis 
(4). Oestradiol implants are not widely available in the 
United Kingdom.
Commonly available option for testosterone therapy 
in the United Kingdom includes 2% transdermal gel 
(Tostran), two intramuscular options testosterone 
propionate 250 mg three weekly (Sustanon) and 
testosterone undecanoate 1000 mg every 12  weeks 
(Nebido). Oral testosterone undecanoate 40 mg 
(Restandol) has recently become unavailable in the 
United Kingdom. The clinic protocol for testosterone 
replacement is to initiate with transdermal or low-
dose injectable forms in combination with oestrogen 
before gradually progressing to testosterone only doses 
equivalent of those used in hypogonadal men.
Of the 154 women with CAIS who have attended 
the clinics at UCLH, consent for data analysis and 
adequate HRT data were available in 141 (92%). Data 
extracted included demographics, presentation, age 
of gonadectomy and historical details of their HRT. 
Ethical approval by the Chelsea and Westminster Ethics 
Committee was obtained to review our dataset of medical 
and psychosocial outcomes in disorders of reproductive 
development (Integrated Research Application System 
number 184846). Data are presented as median (range).
Results
For the 141 women with CAIS in the study group, the 
median age of the women at their last attendance was 32 
(16–69) years and age of diagnosis was 16 (0–38) years. 
The most common reason for diagnosis was primary 
amenorrhoea in 54% followed by hernia in childhood 
(29%) and family history of CAIS (16%). One woman 
presented with discordance in amniocentesis karyotype 
and birth phenotype. Past history of hernia was present 
in 59%, which was identified at age 1.5 (0.1–24) years. 
Gonadectomy had been deferred indefinitely (n = 13) or 
was pending (n = 3) in 16/141 (11%). In the remainder, the 
age of gonadectomy was 17 (0.1–53) years.
The median age of initiation of HRT was 18 (8–41) 
years. Table 1 shows the HRT choices of the 141 women 
of whom 23 did not require HRT either because gonads 
were in situ or they had chosen to stop HRT either because 
of intolerance or because it was age appropriate. The 
most common form of HRT was some form of oestrogen 
in 113/141 (80%) of the total group or 96% or those 
requiring HRT. Vaginal oestrogens alone (n = 1) or together 
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with systemic sex steroids (n = 12) were required in 13/141 
(9%) women.
Testosterone was used in 14/141 (10%) of the total 
group or 12% of women requiring HRT with 8 women 
choosing to combine both oestrogen and testosterone 
treatments and 6 using testosterone alone. The median 
duration of use of testosterone was 4 (1–25) years. Most 
notable was an individual who used Nebido at full dose 
for 25  years with no side effects and well-maintained 
vitality. On review of past HRT experience, a further 10 
individuals had used testosterone therapy in the past 
but had discontinued. The reason for discontinuing 
was almost universally that no meaningful benefit was 
perceived. No side effects to testosterone were recorded in 
routine clinic notes. Overall, therefore 24 (17%) women 
had used testosterone therapy at some time.
Discussion
This study is the first to provide real-life data on the 
hormone treatment choices made by adult women with 
CAIS. Oestrogen was used by 96% of those using HRT and 
testosterone by 12%. Over half (58%) of women who had 
tried testosterone treatment chose to continue at the time 
of assessment.
The most common form of HRT in our study was oral 
oestrogen, followed by transdermal oestrogen. Advantages 
of transdermal over oral oestrogen formulations are well 
known, including a more physiologic mode of delivery, 
decrease hepatic first-pass effect and reduced risk of 
thromboembolism, but oral oestrogen is widely accepted 
by patients owing to the convenience of administration 
(5, 6). The dosage used was based empirically on 
clinical wellbeing reported by the patient. Individuals 
were offered a dose adjustment at each clinic visit with 
physician guidance and with reference to the bone 
mineral density (BMD) measurement. To assist women 
in making the decision, they are informed of their BMD 
result and the general rule was the higher dose of HRT of 
any kind is a benefit to bone density (7, 8). Local vaginal 
oestrogen was used by 9% of women, often prescribed as 
adjuvant therapy for those who require vaginal dilatation. 
Oestrogen implants were previously a popular choice but 
only a few users remained on implants at the time of this 
assessment as this form of treatment is not easily available 
in the United Kingdom.
A proportion of women with CAIS favoured the 
use of testosterone. This group of women were often 
previous users of oestrogen implants, which were an 
ideal option for women without a uterus who required 
an implant only every six months, eliminating the need 
for daily treatment. Intramuscular depot preparation 
of testosterone is a useful alternative requiring only 4 
injections per year. In a small double-blind crossover study, 
there was no difference in psychosexual functioning in 
4 women with CAIS using either androgen or oestrogen 
therapy for 4  weeks (9). A trial comparing the clinical 
and metabolic effects of testosterone and oestradiol in 
adult gonadectomised patients with 46,XY DSD due to 
CAIS is underway but results are not available yet (10). 
Our clinic experience leads us to conclude that controlled 
trials comparing oestrogen and testosterone would be 
extremely difficult because of the subtlety and imprecise 
quantification of outcome measures and because of the 
difficulty of blinding suitably high-dose preparations.
In a study among forty six 46,XY subjects with 
DSD, only 47.8% had an accurate diagnosis (11). With 
Table 1 Treatment choices of 141 women with CAIS.
Type of HRT n % Dose range
Oestrogen 113 80  
 Oral  
  Oestradiol valerate 59 1–6 mg/24 h
  Conjugated equine oestrogen 12  0.2–1.875 mg/24 h
 Transdermal oestradiol 41  25–300 µg/24 h
 Vaginal oestradiol 13   
 Oestradiol implant 3   
Testosterone 14 10  
 Transdermal testosterone 6  Testosterone 2% gel
 Intramuscular testosterone 6  Testosterone undecanoate 1000 mg every 10–12 weeks
   Testosterone propionate 125–250 mg every 1–4 weeks
 Oral testosterone 2  Testosterone undecanoate 40–120 mg
Note that each entry is not mutually exclusive with three individuals using combined oral and transdermal oestrogen, 12 women using vaginal oestrogen 
as a supplement to other sources and 8 using combined oestrogen and testosterone. With regard to testosterone, 5 women on transdermal and one on 
intramuscular used concurrent oestrogen.
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this is mind, one point of caution when considering 
testosterone replacement is that some women with CAIS, 
particularly those with gonadectomy before 15  years 
of age, may be testosterone sensitive as mutations of 
steroid 5-alpha-reductase 1 (SRD5A1) or hydroxysteroid 
17-beta dehydrogenase 3 (HSD17B3) can mimic CAIS 
on occasion. If an individual has not had sufficient 
exposure to endogenous testosterone, then we favour 
starting testosterone at low dose for several months. 
Some features of virilisation such as voice change are 
irreversible. For women who have been exposed to 
endogenous testosterone by virtue of late gonadectomy, 
then intramuscular depot preparations of testosterone can 
be commenced directly.
In general, HRT should be administered until the 
age of natural menopause, although extended use 
with monitoring of BMD at regular intervals can be 
considered in women with low BMD in the absence of 
contraindications. Low BMD has been reported in women 
with CAIS owing to low circulating oestrogen before 
gonadectomy or inadequate oestrogen replacement after 
gonadectomy (12). The relatively tall stature of CAIS who 
had late gonadectomy has been interpreted as possible 
evidence of oestrogen deficiency (13). Mizunuma 
demonstrated a drop in BMD after gonadectomy in 2 
subjects with CAIS, followed by an increase after treatment 
with oestrogens (14). Women who had good compliance 
with oestrogen replacement therapy had significantly 
better bone density compared to those who reported 
poor compliance (15). In a separate report, we explored 
the relationship between age of gonadectomy and bone 
density in a subgroup of this cohort (16). It is beyond the 
scope of this paper to address long-term morbidity and 
mortality, which would require a much larger study group 
and follow-up time. Long-term outcomes might have to 
be taken into account in the future as more information 
becomes available.
In conclusion, we present the real-life experience 
of women attending a clinic for adults with CAIS in 
making choices for HRT. These observations illustrate a 
personalised approach to care. For many women with 
CAIS, routine oestrogen replacement as for any other form 
of hypogonadism is appropriate. At each visit, a review 
of wellbeing is undertaken, and alternative is considered 
if shortcomings are identified. While the majority of 
women with CAIS choose oestrogen-based treatment after 
gonadectomy, a significant minority prefer testosterone 
and our experience is that this is a satisfactory option. 
Even though no formal safety data are available for the use 
of testosterone in CAIS, we could identify no theoretical 
or practical reason not to offer this option.
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